Millions of people in the world are overweight, and Novo Nordisk hopes to capture a growing share of this lucrative treatment opportunity.
Novo Nordisk (NVO 1.43%) hopes to be the first to market with an oral version of its weight loss treatment.
*Stock prices used were the afternoon prices of Nov. 18, 2025. The video was published on Nov. 20, 2025.
Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.
